Literature DB >> 8113792

Down's syndrome: up-regulation of beta-amyloid protein precursor and tau mRNAs and their defective coordination.

F Oyama1, N J Cairns, H Shimada, R Oyama, K Titani, Y Ihara.   

Abstract

Almost all patients > 40 years of age with Down's syndrome (DS) develop the pathology characteristic of Alzheimer's disease: abundant beta-amyloid plaques and neurofibrillary tangles. We have investigated the gene expression of beta-amyloid protein precursor (APP) and tau in DS and age-matched control brains and found that levels of both mRNAs were significantly elevated in DS. Such up-regulation was not observed in two other neuronal proteins. A correlation between total APP and tau mRNA levels was also found in DS brain but distinct from the pattern observed in normal brain. Although a proportionality existed between APP-695 mRNA and three-repeat tau mRNA in DS, the proportionality between APP-751 mRNA and four-repeat tau mRNA, which is normally present, was not observed. Thus, DS brains are primarily characterized by the up-regulation of tau mRNA as well as APP mRNA and disruption of the coordinate expression between APP-751 and four-repeat tau.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8113792     DOI: 10.1046/j.1471-4159.1994.62031062.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  32 in total

1.  Neuroinflammatory Cytokines-The Common Thread in Alzheimer's Pathogenesis.

Authors:  W Sue T Griffin; Steven W Barger
Journal:  US Neurol       Date:  2010

2.  Amyloid precursor protein-induced axonopathies are independent of amyloid-beta peptides.

Authors:  Gorazd B Stokin; Angels Almenar-Queralt; Shermali Gunawardena; Elizabeth M Rodrigues; Tomás Falzone; Jungsu Kim; Concepción Lillo; Stephanie L Mount; Elizabeth A Roberts; Eileen McGowan; David S Williams; Lawrence S B Goldstein
Journal:  Hum Mol Genet       Date:  2008-08-11       Impact factor: 6.150

Review 3.  Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration.

Authors:  M L Billingsley; R L Kincaid
Journal:  Biochem J       Date:  1997-05-01       Impact factor: 3.857

Review 4.  Neuropathological correlates of amyloid PET imaging in Down syndrome.

Authors:  Eric E Abrahamson; Elizabeth Head; Ira T Lott; Benjamin L Handen; Elliott J Mufson; Bradley T Christian; William E Klunk; Milos D Ikonomovic
Journal:  Dev Neurobiol       Date:  2019-08-17       Impact factor: 3.964

Review 5.  Tau in Alzheimer disease and related tauopathies.

Authors:  K Iqbal; F Liu; C-X Gong; I Grundke-Iqbal
Journal:  Curr Alzheimer Res       Date:  2010-12       Impact factor: 3.498

Review 6.  Mechanisms and consequences of aneuploidy and chromosome instability in the aging brain.

Authors:  Grasiella A Andriani; Jan Vijg; Cristina Montagna
Journal:  Mech Ageing Dev       Date:  2016-03-21       Impact factor: 5.432

7.  Na,K-ATPase mRNA levels and plaque load in Alzheimer's disease.

Authors:  N B Chauhan; J M Lee; G J Siegel
Journal:  J Mol Neurosci       Date:  1997-12       Impact factor: 3.444

Review 8.  Mechanisms of tau-induced neurodegeneration.

Authors:  Khalid Iqbal; Fei Liu; Cheng-Xin Gong; Alejandra Del C Alonso; Inge Grundke-Iqbal
Journal:  Acta Neuropathol       Date:  2009-01-30       Impact factor: 17.088

9.  Alzheimer's disease amyloid-beta links lens and brain pathology in Down syndrome.

Authors:  Juliet A Moncaster; Roberto Pineda; Robert D Moir; Suqian Lu; Mark A Burton; Joy G Ghosh; Maria Ericsson; Stephanie J Soscia; Anca Mocofanescu; Rebecca D Folkerth; Richard M Robb; Jer R Kuszak; John I Clark; Rudolph E Tanzi; David G Hunter; Lee E Goldstein
Journal:  PLoS One       Date:  2010-05-20       Impact factor: 3.240

10.  Overexpression of FABP7 in Down syndrome fetal brains is associated with PKNOX1 gene-dosage imbalance.

Authors:  Ma Francisca Sánchez-Font; Anna Bosch-Comas; Roser Gonzàlez-Duarte; Gemma Marfany
Journal:  Nucleic Acids Res       Date:  2003-06-01       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.